Cantor Fitzgerald Analysts Give Advaxis (ADXS) a $19.00 Price Target

Advaxis (NASDAQ:ADXS) received a $19.00 price target from research analysts at Cantor Fitzgerald in a report released on Friday, December 22nd. The brokerage presently has a “buy” rating on the biotechnology company’s stock.

Several other brokerages also recently commented on ADXS. BidaskClub raised Advaxis from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. ValuEngine raised Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, September 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a research report on Friday, September 15th.

Shares of Advaxis (NASDAQ:ADXS) opened at $2.96 on Friday. Advaxis has a twelve month low of $2.71 and a twelve month high of $10.06. The firm has a market capitalization of $122.26, a price-to-earnings ratio of -1.28 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). The company had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million. Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. analysts forecast that Advaxis will post -2.36 earnings per share for the current year.

In other news, insider Robert Petit sold 12,625 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total transaction of $40,273.75. Following the transaction, the insider now owns 237,265 shares of the company’s stock, valued at approximately $756,875.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Sara Bonstein sold 12,734 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,621.46. Following the transaction, the chief financial officer now directly owns 244,504 shares in the company, valued at approximately $779,967.76. The disclosure for this sale can be found here. Insiders sold a total of 38,192 shares of company stock worth $122,615 in the last ninety days. 7.21% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of ADXS. Nexthera Capital LP grew its position in shares of Advaxis by 160.3% during the 2nd quarter. Nexthera Capital LP now owns 252,000 shares of the biotechnology company’s stock worth $1,635,000 after buying an additional 155,200 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Advaxis by 9.2% during the 1st quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock worth $13,587,000 after buying an additional 139,710 shares in the last quarter. OxFORD Asset Management LLP bought a new position in shares of Advaxis during the 2nd quarter worth $498,000. DAFNA Capital Management LLC grew its position in shares of Advaxis by 43.6% during the 2nd quarter. DAFNA Capital Management LLC now owns 247,000 shares of the biotechnology company’s stock worth $1,603,000 after buying an additional 75,000 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC grew its position in shares of Advaxis by 117.1% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 129,800 shares of the biotechnology company’s stock worth $369,000 after buying an additional 70,000 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/14/advaxis-adxs-pt-set-at-19-00-by-cantor-fitzgerald.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply